Corwave

High-Level Overview

CorWave is a French medtech company developing innovative implantable blood pumps using patented wave membrane technology to treat advanced heart failure patients. It builds left ventricular assist devices (LVADs) that mimic the heart's natural pulsatile flow, serving patients awaiting transplants or needing long-term cardiac support, addressing high adverse event rates and poor quality of life from existing rotary pumps.[1][3][4][5] With over €80 million raised, including a €35 million Series C in 2024 with EIC Fund participation, CorWave employs 90+ people and shows strong growth via preclinical milestones, manufacturing expansion, and key hires like VP Operations and CFO.[1][3][4]

Origin Story

CorWave originated from the 1996 invention of wave membrane technology by Jean-Baptiste Drevet, who collaborated with CNRS and founded AMS R&D. In 2012, MD Start—a Sofinnova Partners medtech accelerator—incorporated CorWave, securing an exclusive license from AMS R&D and joining Agoranov Incubator.[2][4][5] Early traction included €3.3 million Series A in 2013 from Bpifrance, Seventure Partners, and Sofinnova, plus the first US patent and scientific presentations.[4] Pivotal moments: 60-day chronic preclinical study in 2019, awards like KPMG Tech Pulse 40, and recent progress like a 6-month in vivo study completion, new Paris manufacturing facility, and French Tech 120 recognition.[1][4]

Core Differentiators

CorWave stands out in the LVAD market through:

• Wave membrane technology: Patented oscillating membrane mimics marine propulsion for gentle, physiological pulsatile blood flow, unlike rotary pumps causing continuous flow and adverse events like clots or bleeding.[1][3][5]
• Improved biocompatibility and efficiency: Reduces energy use, enhances blood handling, and targets fewer rehospitalizations for better patient quality of life.[2][5]
• Expert team ("CorWavers"): 90+ international specialists with 40+ prior medtech successes, focused on implantables, test benches, surgical tools, and programs like mini-invasive "Nemo" pump.[2]
• Development momentum: Preclinical validation complete, first-in-human trials imminent, backed by MD Start's hands-on acceleration and investors like Sofinnova.[1][4][5]

Role in the Broader Tech Landscape

CorWave rides the heart failure medtech wave, targeting 60 million global patients where LVADs fill a $1 billion market gap amid donor shortages and poor rotary pump outcomes.[5] Timing aligns with aging populations, rising chronic disease, and EU innovation funding like EIC, enabling scale-up in France's medtech hub.[3][4] Favorable forces include regulatory progress toward trials and industrial biotech trends for sustainable devices; CorWave influences the ecosystem via MD Start's model, fostering European deep-tech startups and reducing therapy costs through fewer adverse events.[1][5]

Quick Take & Future Outlook

CorWave is primed for clinical trials post-6-month in vivo success, with production ramp-up via new facility and leadership hires signaling commercialization push. Trends like pulsatile flow adoption and AI-optimized implants will shape growth, potentially expanding to right-heart or mini-invasive applications like Nemo. Its influence may grow as a European LVAD leader, transforming survival for heart failure patients and validating wave tech globally—echoing its mission to enable active lives beyond transplants.[1][2][3][4]